ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Experimental Pharmacology and Drug Discovery
Identify the Therapeutic Role and Potential Mechanism of α-Cyperone in diminished ovarian reserve Based on Network Pharmacology, Molecular docking, Lip-MS and Experimental Validation
Provisionally accepted
- 1Ningxia Medical College, Yinchuan, China
- 2General Hospital of Ningxia Medical University, Yinchuan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: DOR poses a significant threat to female fertility, with no effective treatment available. α-Cyperone (AC) exhibits notable anti-inflammatory and anti-oxidative properties; however, its potential for improving DOR remains unexplored. Methods: The PubChem, PharmMapper, and SwissTargetForecast databases were queried to retrieve biochemical information and drug targets for AC. The identification of disease targets for DOR involved referring to the OMIM and Genecards databases. AC's therapeutic targets against DOR were determined by examining the overlap between drug targets and disease targets. To analyze GO function enrichment, KEGG pathway, and disease association, the Metascape database was utilized. The results were then visualized using Cytoscape. Receptor-ligand interaction between AC and target sites was validated through molecular docking investigations utilizing Pymol and AutoDock program software. The effect of AC on granule cell function was verified in CTX-induced DOR granule cell model. The actual AC-binding proteins in the cells were identified by Lip-MS, and the effects of AC on target protein genes were verified by RT-qPCR. Results: Following the integration of 466 drug targets with 1529 disease targets, we identified 257 AC targets for the treatment of DOR. We recorded the top 20 enriched GO and KEGG pathways that potentially contribute to the anti-DOR effect of AC. Employing the MCC algorithm, we identified key TOP22 proteins. The docking studies revealed that AC binds strongly to all 22 proteins studied. The CTX-induced DOR granule cell model was successfully established, which was verified by detecting the levels of AMH, ROS, MMP and cell viability, indicating that AC enhanced the function of DOR granule cells. The abnormal expression patterns of MAP2K1, AKT1, ESR2, ERBB2, CDH1, CYP19A1, ESR1 and MAPK8 genes were also reversed. In addition, the binding of AC to MAP2K1, GSK3B and MAPK14 was verified by Lip-MS experiments. Conclusions: AC can improve CTX-induced KGN proliferation and the function of KGN cell. The mechanism may be due to the targeted binding ability of AC to domains of MAP2K1, MAPK14 and GSK3B. AC's potential therapeutic targets are comprehensively explored in this study, as well as theoretical support for its use in the treatment of DOR is provided.
Keywords: α-Cyperone, diminished ovarian reserve, Network Pharmacology, molecular docking, experimental validation, Limited proteolysis–mass spectrometry
Received: 02 Jul 2025; Accepted: 03 Dec 2025.
Copyright: © 2025 Guo, Yang, Chen, Hu and Guo. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Rong Hu
Hua Guo
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.